A method for purifying recombinant collagen with reduced host protein content
By using Triton X-100 induced phase separation technology, the problem of HCP removal in recombinant collagen in Pichia pastoris expression system has been solved, achieving efficient and simple removal of host cell proteins, improving product safety and appearance quality, and making it suitable for a variety of application scenarios.
Patent Information
- Application Number
- CN202611626980.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-21
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies for removing host cell proteins (HCPs) from recombinant collagen in Pichia pastoris expression systems are lengthy, costly, and fail to meet the industry's stringent requirements for HCP residue levels. In particular, the removal of alcohol oxidase (AOX) polymers is difficult, affecting product safety and appearance quality.
Using the Triton X-100 induced phase separation technology, HCP is associated with Triton X-100 micelles by heating to 60-100℃ after low-temperature incubation, forming a micelle-rich phase and an aqueous phase, which selectively removes host cell proteins, especially AOX octamers.
It significantly reduces HCP residue, improves product appearance, simplifies production processes, reduces costs, meets industry standards, and is suitable for the purification of injectable and cosmetic-grade recombinant collagen.
Smart Images

Figure CN123106883A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of bioengineering technology, specifically to a method for purifying recombinant collagen with reduced host protein content. Background Technology
[0002] Collagen is a major component of the extracellular matrix and possesses key biological activities such as promoting fibroblast proliferation and repair, and guiding tissue regeneration, making it widely used in the pharmaceutical and aesthetic fields. Compared with animal-derived collagen, recombinant humanized collagen, prepared through genetic engineering techniques (such as the Pichia pastoris expression system), has significant advantages such as sequence controllability, good water solubility, low immunogenicity, and no risk of viral contamination, making it a key area of current biomaterials research and development.
[0003] During the high-density fermentation expression of recombinant collagen using Pichia pastoris, residual host cell impurities are inevitably introduced, with host cell proteins (HCPs) being the most significant category. HCPs are complex mixtures of heterologous proteins, and their residues can not only trigger immune responses and affect product safety but also significantly reduce product purity and stability. Specifically, residual yeast HCPs, acting as exogenous antigens, can stimulate the body to produce antibodies, leading to reduced product efficacy or even inducing allergic or inflammatory reactions, posing a significant safety threat for injectable or implantable medical devices. Furthermore, some HCPs possess protease activity, which can continuously degrade the target collagen, resulting in decreased product bioactivity and shortened shelf life.
[0004] In the Pichia pastoris methanol-induced expression system, alcohol oxidase (AOX) is a highly abundant and representative component of hematopoietic oxidase (HCP). During the later stages of fermentation, AOX is released into the culture supernatant due to cell lysis and readily forms a homooctamer bound to the FAD cofactor. This multimer not only significantly increases the difficulty of HCP removal, but its strong yellow-green appearance also directly causes the recombinant collagen product to exhibit a yellow-green color, severely affecting the product's appearance quality and subsequent applications.
[0005] To ensure the safety and efficacy of recombinant collagen products, relevant domestic and international industry standards and technical specifications have imposed strict limits on the residual amount of host cell protein (HCP). For example, some industry standards specify differentiated HCP residue limits for different application scenarios: for medical device-grade products used for implantation or injection, the HCP residue should not exceed 0.05% (i.e., 500 ppm); while for products used as raw materials for topical or cosmetic applications, the HCP residue should not exceed 0.1% (i.e., 1000 ppm). Furthermore, some group standards stipulate that the HCP residue in soluble collagen raw materials for cosmetic use should not exceed 0.1% (i.e., 1000 ppm). Therefore, controlling HCP residue is one of the core indicators for quality control and safety evaluation of recombinant collagen products, regardless of whether they are used in medical implantation, injection, or cosmetic applications.
[0006] Currently, the deep removal of HCP from recombinant collagen typically relies on multi-step chromatographic processes based on different principles. A typical process includes: mixed mode chromatography (MMC) / ion exchange chromatography (IEX) - hydrophobic chromatography (HIC) - molecular sieve chromatography (SEC), interspersed with ultrafiltration / percolation steps. While this "layered chromatography" strategy is effective, it suffers from drawbacks such as lengthy processes, yield loss, and high costs. Therefore, developing a simpler, lower-cost HCP removal process that can efficiently integrate or replace traditional chromatographic steps is of significant industrial value for improving the quality of recombinant collagen products, reducing production costs, and meeting regulatory requirements. Summary of the Invention
[0007] In view of the shortcomings of the prior art, the present invention discloses a purification method for removing host cell proteins from a Pichia pastoris expression system that is simple to operate, has mild conditions, and is highly efficient.
[0008] To achieve the above technical objectives, this invention proposes a method for purifying recombinant collagen with reduced host cell protein content. The method includes: mixing an initial recombinant collagen solution with Triton X-100, incubating at -1°C to 10°C, and then raising the temperature to 60 to 100°C to induce phase separation, forming a Triton X-100-rich micelle phase and an aqueous phase; separating and collecting the aqueous phase to obtain a recombinant collagen solution with reduced host cell protein content.
[0009] Based on extensive experiments, the research team of this invention unexpectedly discovered that using Triton X-100 for induced phase separation under specific temperature conditions can effectively remove HCP from the initial recombinant collagen solution. The team hypothesizes that the synergistic effect of low-temperature incubation, relatively high-temperature induced phase separation, and Triton X-100 induces differentiated higher-order structural rearrangements in host cell proteins. Specifically, on the one hand, multimeric components in HCP (such as AOX octamers) depolymerize, disrupting their original higher-order structure and significantly increasing the exposure of internal hydrophobic regions; on the other hand, other protein components undergo varying degrees of conformational unfolding, with significantly enhanced molecular surface hydrophobicity. Both of these changes significantly enhance the association ability between HCP and Triton X-100 micelles, resulting in a significant difference in the partitioning behavior of HCP between the micelle-rich phase and the aqueous phase. This leads to the selective enrichment of host cell proteins in the micelle-rich phase, achieving effective separation from recombinant collagen.
[0010] The above technical solution is simple to operate. After induced phase separation, significant HCP removal can be achieved simply by separating the aqueous phase, resulting in a recombinant collagen solution that meets safety and efficacy requirements. Furthermore, the research team unexpectedly discovered through experiments that induced phase separation using Triton X-100 has a significant decolorizing effect on recombinant collagen, changing the product solution color from yellow-green to pale yellow. This invention demonstrates that the above technical solution is particularly suitable for solving solution color problems caused by host proteins, improving product purity from the source while simplifying the production process and reducing overall costs.
[0011] Further, the concentration of recombinant collagen in the initial recombinant collagen solution is 1-100 mg / ml, preferably 1-30 mg / ml, more preferably 2-15 mg / ml, even more preferably 3-5 mg / ml, and even more preferably 3-3.5 mg / ml.
[0012] Furthermore, the final concentration of Triton X-100 is 1% to 10% (v / v), preferably 1% to 5% (v / v), more preferably 1.5% to 3% (v / v), and even more preferably 2% (v / v).
[0013] In the above technical solution, adding Triton X-100 to the protein solution to be treated, mixing thoroughly, and then incubating facilitates the full interaction between Triton X-100 and impurities such as host cell proteins. Further, the incubation operation is performed at -1℃ to 10℃ for 0.5 to 12 hours; low-temperature incubation promotes association between HCP and Triton X-100 micelles. In an optional example of the present invention, the incubation operation is performed at 2 to 8℃ for 2 to 5 hours.
[0014] In the above technical solution, the incubated system is heated to 60-100℃ and allowed to stand at this temperature to induce phase separation, forming a water-rich phase and a micelle-rich phase. Further, the temperature for inducing phase separation is 70-90℃, preferably 70-75℃. Further, the processing time for the phase separation operation is 10-60 min, preferably 15-30 min. Further, the operation of separating and collecting the aqueous phase includes centrifugation, ultrafiltration, or static separation, thereby completing the removal of host cell proteins, which can be selected as needed in actual operation.
[0015] Furthermore, after the host cell protein content is reduced, the treatment further includes ultrafiltration concentration and / or chromatographic purification steps to further refine the recombinant collagen. Even further, after the host cell protein content is reduced, multi-mode chromatography or ultrafiltration concentration is performed, eliminating the need for complex chromatographic equipment and expensive chromatographic media, thus obtaining a high-quality recombinant collagen product with a host protein content meeting industry standards. Furthermore, the removal rate of the host cell protein is greater than 90%, preferably greater than 95%, resulting in high product safety and broadly expanding the application areas and usage scenarios of recombinant collagen.
[0016] Compared with existing technologies, the beneficial effects of this invention are as follows: By mixing the initial recombinant collagen solution with Triton X-100, incubating at low temperature, and then raising the temperature to 60-100℃ to induce phase separation and collect the aqueous phase, this invention can significantly reduce the residual host cell protein in the solution, especially showing a good removal effect on chromogenic HCP components such as alcohol oxidase, improving the product appearance from yellow-green to light yellow, and making it easier to meet the relevant standards for HCP residue limits; at the same time, this method can achieve the HCP removal level that traditional processes require one or more steps of chromatography through only one chemical treatment, without relying on complex chromatography equipment and expensive chromatography media, and can directly replace or simplify specific steps in existing purification processes, greatly shortening the production cycle; moreover, the reagents used are inexpensive and the operation is simple, significantly reducing material costs and equipment investment, and has good prospects for industrial scale-up and economic benefits. Attached Figure Description
[0017] The accompanying drawings, which form part of this application, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an undue limitation of the invention. In the drawings: Figure 1 The appearance of the recombinant collagen solution with reduced host cell protein content obtained from the medium concentration control group and the experimental group in Example 1 is shown in comparison. Detailed Implementation
[0018] To facilitate understanding of the present invention, a more comprehensive description will be provided below, along with preferred embodiments. However, it should be understood that these embodiments are merely for more detailed explanation and should not be construed as limiting the invention in any way, i.e., not intended to limit the scope of protection of the invention.
[0019] Unless otherwise defined, the technical terms used in the following embodiments have the same meanings as commonly understood by those skilled in the art to which this invention pertains. Unless otherwise specified, the experimental reagents used in the following embodiments are conventional biochemical reagents; and the experimental methods described are conventional methods.
[0020] Furthermore, it should be noted that although the various steps of the preparation method of the present invention are described in a specific order in the description of the present invention, these orders are not restrictive. Without departing from the basic principles of the present invention, those skilled in the art can perform the steps in different orders.
[0021] All numerical designations, such as time, temperature, dosage, and range, are approximate values. It should be understood that, while not always explicitly stated, all numerical designations are preceded by the term "approximately." It should also be understood that, while not always explicitly stated, the reagents described herein are merely examples, and their equivalents are known in the art.
[0022] When a quantity, concentration, or other value or parameter is expressed as a range, a preferred range, or a range defined by a series of upper and lower preferred values, this should be understood as specifically disclosing all ranges formed by any pair of any upper or preferred value with any lower or preferred value, regardless of whether the range is disclosed individually. For example, when the range “1–5” is disclosed, the described range should be interpreted as including ranges “1–4”, “1–3”, “1–2”, “1–2 and 4–5”, “1–3 and 5”, etc. When numerical ranges are described herein, unless otherwise stated, the range is intended to include its endpoints and all integers and fractions within that range.
[0023] The materials and methods involved in the embodiments of the present invention include: Initial recombinant collagen solution: The recombinant collagen was derived from a recombinant human type I collagen solution expressed by Pichia pastoris fermentation and preliminarily purified, and adjusted to a suitable concentration with physiological saline.
[0024] Main reagent: Triton X-100 is chemically pure.
[0025] Reference standard: alcohol oxidase (AOX) 50 U / ml.
[0026] Yeast host detection kit: Cygnus Technologies Item No.: F140.
[0027] Main instruments: shaker, high-speed refrigerated centrifuge, enzyme-linked immunosorbent assay (ELISA) reader, endotoxin detector, ultraviolet spectrophotometer, and constant temperature water bath.
[0028] Example 1
[0029] A method for purifying recombinant collagen with reduced host protein content, specifically: (1) Sample processing: Take three different concentrations (low concentration 1.0 mg / ml, medium concentration 3.4 mg / ml, high concentration 30 mg / ml), 20 mL of each protein solution, and dispense them into two 15 mL centrifuge tubes, 10 mL per tube, two tubes per group, and label them as control group and experimental group respectively.
[0030] In this embodiment, recombinant collagen with the amino acid sequence shown in SEQ ID NO.1 is used as an example to illustrate the purification process and its effects. Optionally, the preparation method of the recombinant collagen includes: constructing an engineered bacterium expressing the sequence shown in SEQ ID NO.1 through genetic engineering; after fermentation, the supernatant is collected by centrifugation, concentrated by ultrafiltration, precipitated by ammonium sulfate, and subjected to complex-mode chromatography to obtain recombinant collagen with a purity ≥95%. Optionally, physiological saline may be used to adjust the recombinant collagen to a suitable concentration.
[0031] SEQ ID NO.1: DGVAGPKGPAGERGSDGPAGPKGSPGEAGRPGEAGLPGAKGLTGSPGSPGPDGKTGPPGPAGQDGRPGPPGPPGARGQAGVMGFPGPKGAAGEPGKAGERGVPGPPGAVGPAGKDGEAGAQGPPGPAGPALS VDGERGEQGPAGSPGFQGLPGPAGPPGEAGKPGEQGVPGDLGAPGPSGARGERGFPGERGVQGPPGPAGPRGANGAPGNDGAKGDAGAPGAPGSQGAPGLQGMPGERGAAGLPPGKGERGDAGPKGADGSEG.
[0032] (2) Adding surfactant and incubating at low temperature: Triton X-100 was added to the low-concentration, medium-concentration, and high-concentration experimental group samples respectively, so that the final concentrations (v / v) were 1%, 2%, and 10%, respectively, and the corresponding added volumes were 0.1 ml, 0.2 ml, and 1 ml, respectively; an equal volume of PBS buffer was added to each control group. The centrifuge tubes of each group of samples were shaken to mix well and incubated at 2℃~8℃ for about 4 h.
[0033] (3) Heating to induce phase separation: The centrifuge tubes of the experimental group and the control group were transferred to a 75°C water bath and kept at the temperature for 15 minutes to induce phase separation. The experimental group solution became turbid and showed signs of stratification.
[0034] (4) Phase separation and collection: Both sets of centrifuge tubes were immediately centrifuged at 4030 r × g for 10 min. After centrifugation, the experimental group system was clearly separated into two phases: the lower layer was a micelle-rich phase and the upper layer was an aqueous phase. The upper aqueous phase was carefully aspirated and collected using a pipette. The appearance comparison of the recombinant collagen solutions collected from the control group and the experimental group is shown in the figure. Figure 1 .
[0035] Subsequently, the protein content (BCA method), endotoxin content (Limulus amebocyte lysate (LAL) reagent method), yeast HCP content (ELISA), and AOX content (ELISA) of the collected recombinant collagen solutions from the experimental and control groups were detected. The results are summarized in Table 1.
[0036] Table 1. HCP residues after treatment of collagen solutions of different concentrations under different conditions.
[0037] As shown in Table 1, the HCP removal rate in the experimental groups was no less than 76% (76%–91%). Considering both protein recovery rate and HCP removal rate, the recombinant collagen in the medium-concentration experimental group showed the best recovery and HCP removal effects. Figure 1Compared to the yellow-green appearance of the control group, the experimental group treated with Triton X-100 high-temperature phase separation showed a pale yellow clear liquid under medium concentration conditions. This directly confirmed that chromogenic host cell proteins such as AOX were effectively removed, significantly improving the appearance quality of the recombinant collagen solution. Referring to Table 1, the concentration of recombinant collagen in the initial recombinant collagen solution can be selected as 1-100 mg / ml, more preferably 1-30 mg / ml, more preferably 2-15 mg / ml, even more preferably 3-5 mg / ml, and even more preferably 3-3.5 mg / ml; the final concentration of Triton X-100 can be selected as 1%-10% (v / v), preferably 1%-5% (v / v), more preferably 1.5%-3% (v / v), and even more preferably 2% (v / v); by matching a suitable initial recombinant collagen concentration and a suitable final concentration of Triton X-100, Triton X-100 can effectively form micelles in the protein solution and maintain a suitable micelle-protein ratio, thereby efficiently inducing phase separation, promoting the selective allocation of host cell proteins to the micelle-rich phase, and simultaneously obtaining a high recovery rate of recombinant collagen in the aqueous phase.
[0038] Example 2 Based on the purification process shown in Example 1, the research team also set up different experimental groups using different surfactants or treatment conditions to analyze the recovery rate of collagen and the removal rate of HCP after treatment. The specific operations are as follows: The initial recombinant collagen solution was aliquoted into six 15 mL centrifuge tubes, each containing 10 mL, and labeled. Surfactants were added to the experimental group tubes, the mixture was shaken to mix, and after low-temperature incubation, the induction phase was increased. The treatment conditions for each group are shown in Table 2. Experimental group F was treated with 1% activated charcoal, while the others were treated as shown in Table 2. The supernatant aqueous phase solutions were then analyzed for protein content (BCA method), endotoxin content (Limulus amebocyte lysate (LAL) method), and yeast HCP content (ELISA). The results and statistical analysis are shown in Table 2.
[0039] Table 2. Collagen recovery rate and HCP residue under different treatment conditions
[0040] Table 2 confirms that the Triton X-114 control (Group E) failed to effectively induce phase separation at 37℃, with HCP residue reaching as high as 28 μg / mL (approximately 8800 ppm), exhibiting a yellow-green appearance and poor removal efficiency. The activated carbon control (Group F) showed HCP residue of 24 μg / mL (approximately 10000 ppm) and the lowest collagen recovery rate (67.60%), indicating non-specific adsorption loss of the target protein. In contrast, the experimental groups with Triton X-100 significantly reduced HCP and AOX residues while maintaining a high collagen recovery rate. Specifically, the solutions obtained from experimental groups A through D were all slightly yellow and clear liquids, while the solution treated with Triton X-114 at 37℃ (Group E) remained a yellow-green clear liquid, and the activated carbon treatment (Group F) also resulted in a slightly yellow solution with extremely high HCP residues. This result demonstrates that Triton X-100 combined with high-temperature phase separation has a significant advantage in removing AOX (the main source of the yellow-green color) and HCP.
[0041] Furthermore, based on Table 2, it can be verified that the temperature for the induced phase separation is 70~90℃, preferably 70~75℃, and more preferably 75℃; the processing time for the induced phase separation operation is 10~60min, preferably 15~30min, and more preferably 15min; thus, better host protein removal rate and recombinant collagen recovery rate can be obtained.
[0042] Example 3 Based on the technical advantage of efficient HCP removal in Example 1, subsequent purification operations can be simplified, thereby effectively streamlining the process and reducing operational difficulty. In this example, the recombinant collagen solution with reduced host cell protein content obtained in Example 1 and the initial recombinant collagen solution are used for further purification to explore a process for deep HCP removal.
[0043] Sample setup: 10 mL of initial recombinant collagen solution (control sample); 10 mL of recombinant collagen solution with reduced host cell protein content obtained in Example 1 after Triton-X100 treatment (experimental sample).
[0044] Purification media: 5ml pre-packed Smac MMC column; 5ml pre-packed Phenyl HF column.
[0045] Test reagent: Yeast host test kit: Cygnus Technologies Item No.: F140.
[0046] Main instruments: medium-pressure chromatography system, shaking mixer, high-speed refrigerated centrifuge, enzyme-linked immunosorbent assay (ELISA) reader, endotoxin detector, ultraviolet spectrophotometer, and constant temperature water bath.
[0047] Test method: (1) Purification process: The two groups of samples were run in parallel with a two-step purification process.
[0048] Step 1: Multimode chromatography (MMC), process conditions: Equilibration: 20 mM sodium phosphate buffer, pH 6.5; Loading: Sample A and Sample B were loaded at a flow rate of 1 mL / min; Eluting: Eluting with equilibration buffer for 5 column volumes (CV) until the baseline stabilized; Elution: Elution was performed with 20 mM sodium phosphate buffer (containing 0.5 M NaCl, pH 6.5), and the elution peak was collected.
[0049] Step 2: Hydrophobic chromatography (HIC), process conditions: Equilibration: 20 mM sodium phosphate buffer + 1 M ammonium sulfate, pH 7.0; Loading: Adjust the MMC elution buffer to the same conductivity and pH as the equilibration buffer, and load the sample at a flow rate of 0.5 mL / min; Eluting: Elute with equilibration buffer for 5 CV; Elution: Perform linear gradient elution (0–100% B, 10 CV) with 20 mM sodium phosphate buffer (pH 7.0), and collect the elution peaks.
[0050] (2) Sample testing The purity and HCP content (ppm) of the test samples and intermediate samples after each purification step were analyzed. The sample numbering rules are shown in Table 3.
[0051] Table 3
[0052] Brief description of detection methods: Total protein content was determined using the BCA method, and HCP content was detected using a Pichia pastoris host cell protein ELISA kit. The relative HCP content (ppm) was calculated using the following formula: Relative HCP content (ppm) = HCP content (μg / ml) / Total protein content (mg / ml) × 1000. Collagen protein purity was detected using the SDS-PAGE method. The detection results are shown in Table 4.
[0053] Table 4
[0054] Table 4 confirms that the HCP content of samples A-1 and A-2 in series A is less than 500 ppm, while only sample B-2 in series B has an HCP content less than 5.0 × 10⁻⁶ ppm. 2 ppm. After pretreatment with Triton X-100 induced phase separation, the HCP content of the experimental group's feed solution decreased from 9.4 × 10⁻⁶ ppm to that of the control group. 3 The concentration of ppm decreased significantly to 8.7 × 10⁻⁶. 2ppm; subsequent single-step purification using multi-mode chromatography (MMC) can further reduce HCP to 1.6 × 10⁻⁶ ppm. 2 ppm (<5.0×10 2 The concentration of HCP in the control group was 1.0 × 10⁻⁶ ppm, meeting the relevant standard requirements. In contrast, the HCP in the control group, even after one-step purification with MMC, was still as high as 1.0 × 10⁻⁶ ppm. 3 To achieve the required ppm level, an additional hydrophobic chromatography (HIC) step is necessary. Therefore, this invention utilizes a pre-treatment with Triton X-100 phase separation, eliminating the need for subsequent HIC purification steps and enabling one-step purification of MMC to meet the standard. This significantly simplifies the process, shortens the production cycle, and reduces purification costs.
[0055] It should be noted that the above description is a further detailed explanation of the present invention in conjunction with specific embodiments, and it should not be construed that the specific implementation of the present invention is limited to these descriptions. For those skilled in the art, several simple improvements can be made without departing from the concept of the present invention, and all such improvements should be considered to fall within the scope of protection of the present invention.
Claims
1. A method for purifying recombinant collagen with reduced host protein content, characterized in that, include: The initial recombinant collagen solution was mixed with Triton X-100 and incubated at -1°C to 10°C. Then, the temperature was raised to 60 to 100°C to induce phase separation, forming a Triton X-100-rich micelle phase and an aqueous phase. The aqueous phase was separated and collected to obtain a recombinant collagen solution with reduced host cell protein content.
2. The method for purifying recombinant collagen with reduced host protein content according to claim 1, characterized in that, The concentration of recombinant collagen in the initial recombinant collagen solution is 1–100 mg / ml; And / or, the final concentration of the Triton X-100 is 1% to 10% (v / v).
3. The method for purifying recombinant collagen with reduced host protein content according to claim 2, characterized in that, The concentration of recombinant collagen in the initial recombinant collagen solution is 1~30 mg / ml; And / or, the final concentration of the Triton X-100 is 1% to 5% (v / v).
4. The method for purifying recombinant collagen with reduced host protein content according to claim 3, characterized in that, The concentration of recombinant collagen in the initial recombinant collagen solution is 2–15 mg / ml; And / or, the final concentration of the Triton X-100 is 1.5% to 3%.
5. The method for purifying recombinant collagen with reduced host protein content according to claim 4, characterized in that, The concentration of recombinant collagen in the initial recombinant collagen solution is 3-5 mg / ml; And / or, the final concentration of the Triton X-100 is 2%.
6. The method for purifying recombinant collagen with reduced host protein content according to claim 1, characterized in that, The incubation period is 0.5 to 12 hours.
7. The method for purifying recombinant collagen with reduced host protein content according to claim 6, characterized in that, The incubation operation is carried out at 2~8℃ for 2~5 hours.
8. The method for purifying recombinant collagen with reduced host protein content according to claim 1, characterized in that, The temperature for induced phase separation is 70–90°C; And / or, the processing time for the induced phase separation operation is 10 to 60 minutes; And / or, the operation of separating and collecting the aqueous phase includes centrifugation, ultrafiltration, or settling.
9. The method for purifying recombinant collagen with reduced host protein content according to claim 1, characterized in that, After the host cell protein content is reduced, the process also includes: ultrafiltration concentration and / or chromatography purification steps; The chromatographic purification is selected from one or more of multimode chromatography, ion exchange chromatography, and molecular sieve chromatography.
10. The method for purifying recombinant collagen with reduced host protein content according to claim 9, characterized in that, After the host cell protein content is reduced, multimodal chromatography or ultrafiltration concentration is performed.
